mFOLFIRINOX Does Not Improve DFS in High-Risk Colon Cancer

1 source1 article First seen 6 hours ago Updated 6 hours ago United Kingdom Truth score 38

Save Like Comments Compare coverage

Summary

Adding irinotecan to adjuvant oxaliplatin-based chemotherapy does not improve 3-year disease-free survival in patients with resected, high-risk stage III colon cancer, a phase 3 trial finds. Medscape News UK

Description from Medscape.

Who is covering this

Medscape Center Factuality: Mostly factual US 6 hours ago
mFOLFIRINOX Does Not Improve DFS in High-Risk Colon Cancer
Adding irinotecan to adjuvant oxaliplatin-based chemotherapy does not improve 3-year disease-free survival in patients with resected, high-risk stage III colon cancer, a phase 3 trial finds. Medscape News UK

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

In this story

Medscape News

Filter the stories

Sources Ratings and details

mFOLFIRINOX Does Not Improve DFS in High-Risk Colon Cancer

Summary

Who is covering this

Comments

Summary

Who is covering this

Comments

Related stories

Pharmacist Clinics Raise Heart Failure Therapy Rates to 95%

MPs Have 'No Faith' in Government's Obesity 'Moonshot'

Needs-Led ADHD Triage Pilot Reports Early Results

Spanish Study Finds Rise in Inflammatory Myopathy Admissions

High hsCRP Levels Tied to Worse Outcomes in Kidney Disease

Antibiotic Overuse in COVID Tied to Higher Risk for Death